周一“星”视角|奥希替尼新辅助和辅助治疗IA- IIIA期EGFR突变型NSCLC；基于蛋白质组学的血浆生物标志物预测肺癌多事件

文章预览

本期胸小星将为大家带来 奥希替尼新辅助和辅助治疗IA- IIIA期EGFR突变型NSCLC；基于蛋白质组学的血浆生物标志物预测肺癌多事件， 一起来看看吧！ 2017·EATTS  01 Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA) Jii Bum Lee 1, Su-Jin Choi 1, Hyo Sup Shim 2, Byung Jo Park 3, Chang Young Lee 3, Sumedha Sudhaman 4, Sharlene Velichko 4, Min Hee Hong 1, Byoung Chul Cho 1, Sun Min Lim 5 1 Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. 2 Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea. 3 Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea. 4 Natera, Inc., Austin, Texas, United States of America. 5 Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic o ………………………………